A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With Metastatic Breast Cancer
This study is being done to find out what side effects are caused in participants with breast cancer who are given SGN-LIV1A. This study will also look at other effects of SGN-LIV1A, including its effect on your type of cancer.
Triple Negative Breast Cancer
18 Years and older females
Part D: Metastatic triple-negative disease and received one prior chemotherapy regimen for metastatic disease
Part E: Metastatic hormone receptor-positive disease or triple-negative breast cancer and received one prior hormonal or chemotherapy for metastatic disease
18 - 100
Healthy Volunteers Needed
Duration of Participation
You will receive the study drug for as long as your cancer does not get worse or you do not have bad side effects. After you finish study drug the investigator and/or study team will continue to watch you for side effects and follow your condition either with follow-up clinic visits or follow-up phone calls every 12 weeks for the first year and then every 24 weeks until the study has been completed.
Knight Cancer Institute Clinical Trials
Seattle Genetics, Inc